Results: Of ninety (90) patients enrolled, 66 were male (73.3%) and 24 were female (26.7%); majority with chronic hepatitis B. Sixty (66.7%) of the 90 patients were found to have large EV. The distribution of large EV according to CTP classification was as follows: A, 63.16%; B, 62.8% and C, 75%. Large EV was independently associated with total bilirubin higher than 1.9 mg/dL (p = 0.010), INR higher than 1.65 (p = 0.018), Wnt mutation and platelet count lower than 105,500/mm3 (p = 0.02). Platelet count lower
than 105,500/mm3 had the highest discriminative value for presence of large EV (sensitivity = 73.33%; specificity = 73.33%; area under receiver operating characteristics = 0.783). Conclusions: Large EV were found in 66.7% of patients with liver cirrhosis who underwent hospitalization. In patients with liver cirrhosis, the existence of thrombocytopenia may predict large EV which warrant prophylactic therapy. Key Word(s): 1. large esophageal varices; 2. liver cirrhosis; 3. platelets Presenting Author: www.selleckchem.com/products/Everolimus(RAD001).html LU CHIN HUANG Additional Authors: MING CHE LEE, YUNG HSIANG HSU Corresponding Author: LU CHIN HUANG Affiliations: Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi General Hospital Objective: The patients who had simultaneous hepatocellular carcinoma and cholangiocarcinoma was not frequent. In order to investigate the
manifestations of patients with hepatocholangiocarcinoma, we performed this retrospective study. Methods: From August 1986 to April 2014, the MCE公司 patients with diagnosis of hepatocholangiocarcinoma were included. The age,
gender, alpha fetoprorein (AFP), carbohydrate antigen 19-9 (CA 19-9), HBsAg and anti-HCV was recorded. The size, location of tumor, treatment, follow up duration and survival status was recorded. Results: A total of 10 patients (M 8, F2) were included. The average age was 58.1 years (49–71). The AFP was 38414 ng/mL (5.3–382000 ng/mL, normal <8.1), CA 19-9 was 378 IU/mL (25–1632 IU/mL, normal <37). Hepatitis B, hepatitis C infection rate was 50%, 30%. The size of tumor was 6.7 cm (2–13 cm). The location of tumor was right lobe 50%, left lobe 30%, and both lobes 20%. The treatments included surgery (2), surgery plus chemotherapy (2), surgery plus radiotherapy (2), transarterial chemoembolization (1), chemotherapy (1), and supportive care (2). The follow up duration was 10.6 months (1 month-2.6 years). The 3 months, 6 months, and 1 year survival rate was 90%, 70%, and 55.6%. Conclusion: 1. Hepatocholangiocarcinoma was not a frequent disease. We collected 10 patients in the past 27 years. 2. The average age was 58.1 years. 3. The average AFP was 38414 ng/mL. 4. Hepatitis B, hepatitis C infection rate was 50%, 30%. 5. The 6 months, and 1 year survival rate was 70% and 55.6%, respectively. Key Word(s): 1. hepatocholangiocarcinoma; 2.